Genovis
24,55
SEK
-1,6 %
GENO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1.661 investorer følger denne virksomhed
-1,6%
-12,48%
+5,82%
-14,76%
-52,79%
-51,1%
-62,92%
-2,58%
-10,33%
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Læs mereMarkedsværdi
1,61 mia. SEK
Aktieomsætning
1,01 mio. SEK
Omsætning
158,23 mio.
EBIT %
34,27 %
P/E
26,12
Udbytteafkast, %
-
Finanskalender
14.2
2025
Årsrapport '24
21.5
2025
Delårsrapport Q1'25
12.8
2025
Delårsrapport Q2'25
ViserAlle indholdstyper
Genovis AB: Interim Report January-September 2024
Genovis AB: Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools